Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018-Reference-Cited by-同舟云学术

Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018

Published:2019-04-23 Issue:16 Volume:321 Page:1627
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Hernandez Inmaculada¹,Good Chester B.²,Shrank William H.²³,Gellad Walid F.⁴

Affiliation:

1. Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania

2. Insurance Services Division, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

3. Now with Humana, Louisville, Kentucky

4. Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

http:///jama/article-pdf/321/16/1627/17503400/jama_hernandez_2019_ld_190011.pdf

Reference6 articles.

1. Trends in Medicaid reimbursements for insulin from 1991 through 2014.;Luo;JAMA Intern Med,2015

2. Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013.;Hua;JAMA,2016

3. Why is there no generic insulin? historical origins of a modern problem.;Greene;N Engl J Med,2015

4. Assessment of price changes of existing tumor necrosis factor inhibitors after the market entry of competitors.;San-Juan-Rodriguez;JAMA Intern Med,2019

5. US Food and Drug Administration Center for Drug Evaluation and Research. Approval package for Basaglar. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205692Orig1s000Approv.pdf. Accessed January 7, 2019.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes In Net Prices And Spending For Pharmaceuticals After The Introduction Of New Therapeutic Competition, 2011–19;Health Affairs;2023-08-01

2. Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs;PLOS ONE;2023-01-19

3. Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary;Clinical Pharmacology & Therapeutics;2022-11-04

4. The Impact of Mandatory Nonmedical Switching From Originator to Biosimilar Insulin Glargine;Clinical Therapeutics;2022-07

5. Effectiveness, safety and treatment adherence of biosimilar follow‐on insulin in diabetes management;Diabetes, Obesity and Metabolism;2022-06-28